InspireMD

Explore the layers of carotid stent innovation

CGuard® features a dual-layer design with a finely woven, non-metallic MicroNet™ mesh outer layer and an inner stent frame enhanced with SmartFit™ technology.1

MicroNet Mesh-Covered Protection

  • Made from polyethylene terephthalate (PET), a non-metallic material, to enhance endothelialization and lower the risk of thrombosis
  • Closed-cell protection against plaque protrusion with the smallest mesh pore size (~150 – 180 μm)*
  • Defense demonstrated beyond 5 years1**
More Mesh

SmartFit Technology

  • Self-expanding nitinol stent
  • The largest open-cell frame* that allows for flexibility even in challenging or complex anatomies
  • Supports accurate vessel wall apposition without the need for tapered configurations
More Flex
cguard-prime-hero

A strong defense against the risk of both early and late embolization

cguard-prime-tablet
The lowest independently adjudicated 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid intervention2-11
Review More Clinical Evidence

MicroNet™ Mesh-Cover

A finely woven layer of defense
Patented MicroNet mesh technology is designed to reduce stroke during and after cartoid artery stenting
cguard-prime-next-level
Next-level embolization prevention
Traps and seals thrombus and plaque against the vessel wall
cguard-prime-layer-2
Full-length embolic protection
Secured at both the distal and proximal crowns for consistent containment
cguard-prime-layer-3
Non-metallic matters
  • Woven from a single 20μm strand of polyethylene terephthalate (PET)
  • Chosen for biostability and non-thrombogenicity
  • Provides optimal pore size to prevent embolization (average 165μm)

Provides lasting protection against restenosis, reducing the need for reintervention2

cguard-prime-surgeon-promotes-healing
bg-cguard-prime-design

Designed to defend in a broad range of anatomies

SmartFit™ Technology simplifies sizing and eliminates the need for tapered configurations while maintaining optimal placement length regardless of vessel diameter12,13

Flexible

Nitinol frame design on a large open-stent cell platform

Accurate

Minimal foreshortening during placement and predictable coverage upon deployment

Conformable

Encourages natural vessel wall apposition after deployment, mitigating restenosis and reducing thrombus formation

edu-cgp-001-01-conformable
Highly conformable
edu-cgp-001-01-apposition
Designed for complete apposition
SmartFit™ enhances conformability and apposition regardless of vessel tortuosity or diameter
edu-cg-035-01-apposition-macro
edu-cg-035-01-apposition-microct
Tortuous apposition
edu-cg-035-01-conformability-macro
edu-cg-035-01-conformability-microct
Conformability at inner diameter step from 7 to 5 mm
Summary of Safety and Clinical Performance Report

CGuard® is CE MDR Approved

The CGuard® EPS is indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet both criteria outlined below:

  • Patients with neurological symptoms and >50% stenosis of the common or internal carotid artery by either ultrasound or angiogram or patients without neurological symptoms and >80% stenosis of the common or internal carotid artery by either ultrasound or angiogram.
  • Patients having a vessel with reference diameters between 4.8 mm and 9.0 mm at the target lesion.

The following accessories are compatible with the CGuard® Embolic Prevention System:

  • Proximal protective device Inner Diameter ≥2.12mm or ≥0.083" (for example 9F Mo.Ma™ ultra by Medtronic), or comparable.
  • Distal protection device Emboshield™ NAV6 by Abbot Cardiovascular, or comparable.

CGuard® and the InspireMD Logo are registered trademarks of InspireMD, Inc.

Abbott® and Emboshield NAV6™ are registered trademarks of Abbott Laboratories.

Medtronic® and Mo.Ma™ are registered trademarks of Medtronic Corporation.

References:

  1. Musialek P et al. PARADIGM-Extend Prospective Academic Trial: Accumulating long-term evidence for MicroNet™-covered stent safety and stroke prevention efficacy. Presentation at ESC Congress 2019, Paris, France, 31 August 2019 to 4 September 2019.
  2. InspireMD, Inc. C-GUARDIANS Pivotal Trial: Primary Endpoint Clinical Study Report. Version F (Protocol PRO-9017).
  3. Yadav JS, et al. N Engl J Med. 2004 Oct;351(15):1493-1501. doi: 10.1056/ NEJMoa040127.
  4. Matsumura JS, et al. J Vasc Surg. 2012 Apr;55(4):968-76. doi: 10.1016/j.jvs.2011.10.120.
  5. Higashida R, et al. Stroke vol. 41,2 (2010): e102-9. doi: 10.1161/STROKEAHA.109.564161.
  6. Brott TG, et al. N Engl J Med. 2010 Jul;363(1):11-23. doi: 10.1056/NEJMoa0912321. Epub 2010 May 26.
  7. Kwolek CJ, et al. J Vasc Surg. 2015 Nov;62(5):1227-34. doi: 10.1016/j.jvs.2015.04.460.
  8. U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED): Roadsaver/CASPER Carotid Stent System (PMA P210030). Published November 20, 2024
  9. Gray WA, et al. J Am Coll Cardiol Intv. 2025 Feb;18(3):367-76. doi: 10.1016/j.jcin.2024.10.031.
  10. Safian RD, et al. J Am Coll Cardiol. 2006 Jun;47(12):2384-89. doi: 10.1016/j.jacc.2005.12.076.
  11. Langhoff R, et al. Cardiovasc Intervent Radiol. 2025 Mar;Vol 48 427–37. doi:10.1007/s00270-025-04003-z.
  12. Wissgott C, et al. J Endovasc Ther 2017;24(1):130-137
  13. Musialek P, Hopkins LN, Sidiiqui AH. Postepy Kardiol Interwencyjnej
Contact Us
Contact Us
Stay Connected